View Older Stories View More Recent Stories

Aug 27, 2019 07:30AM Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders
Apr 17, 2019 07:30AM Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference
Apr 17, 2019 07:30AM Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference
Feb 25, 2019 06:10AM Spark Therapeutics (ONCE) to be Acquired by Roche for $114.50/Share
Feb 25, 2019 01:00AM Spark Therapeutics Enters into Definitive Merger Agreement with Roche
Feb 25, 2019 01:00AM Spark Therapeutics Enters into Definitive Merger Agreement with Roche
Feb 19, 2019 07:30AM Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress
Feb 19, 2019 07:30AM Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress
Feb 12, 2019 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights
Feb 12, 2019 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights
Jan 31, 2019 07:48AM Spark Therapeutics (ONCE) Plans Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at WORLDSymposium
Jan 31, 2019 07:30AM Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
Jan 31, 2019 07:30AM Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
Jan 2, 2019 07:30AM Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
Jan 2, 2019 07:30AM Spark Therapeutics to Participate in J.P. Morgan Healthcare Conference
Dec 3, 2018 05:54AM Spark Therapeutics (ONCE) Presents Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial
Dec 2, 2018 07:30PM Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition
Dec 2, 2018 07:30PM Spark Therapeutics Announces Updated Data on SPK-8011 from Ongoing Phase 1/2 Dose-escalation Clinical Trial in Hemophilia A at 60th American Society of Hematology (ASH) Annual Meeting and Exposition
Nov 23, 2018 05:48AM Spark Therapeutics (ONCE) Reports European Commission Approval for LUXTURNA (voretigene neparvovec)
Nov 23, 2018 01:15AM European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
Nov 23, 2018 01:15AM European Commission Approves Spark Therapeutics’ LUXTURNA® (voretigene neparvovec), a One-time Gene Therapy for Inherited Retinal Disease Caused by Confirmed Biallelic RPE65 Mutations
Nov 6, 2018 07:30AM Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress
Nov 6, 2018 07:30AM Spark Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Progress
Oct 30, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
Oct 30, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights
Oct 29, 2018 04:55PM Spark Therapeutics (ONCE) Delivers Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA (voretigene neparvovec-rzyl)
Oct 29, 2018 04:53PM Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting
Oct 29, 2018 04:53PM Spark Therapeutics Presents Three Post-hoc Analyses from Phase 3 Clinical Trial of LUXTURNA® (voretigene neparvovec-rzyl) at American Academy of Ophthalmology Annual Meeting
Oct 25, 2018 07:30AM Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases
Oct 25, 2018 07:30AM Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases
Oct 8, 2018 07:31AM Spark Therapeutics (ONCE) Reports New Preclinical Data for Pompe Disease Gene Therapy Candidate, SPK-3006
Oct 8, 2018 07:30AM Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
Oct 8, 2018 07:30AM Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate
Sep 21, 2018 07:18AM Spark Therapeutics (ONCE) Confirms Positive CHMP Opinion for One-time Gene Therapy LUXTURNA
Sep 21, 2018 07:17AM Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
Sep 21, 2018 07:17AM Spark Therapeutics Announces Positive CHMP Opinion for One-time Gene Therapy LUXTURNA® (voretigene neparvovec) in the European Union
Aug 7, 2018 07:30AM Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
Aug 7, 2018 07:30AM Spark Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Progress
Aug 3, 2018 07:30AM Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
Aug 3, 2018 07:30AM Spark Therapeutics Recognized for Second-straight Year as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
Jul 31, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights
Jul 31, 2018 07:30AM Spark Therapeutics to Host Conference Call on Tuesday, Aug. 7 at 8:30 a.m. ET to Discuss Second Quarter Results and Recent Business Highlights
Jul 16, 2018 10:31AM Pfizer (PFE), Spark (ONCE) Initiate Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
Jul 16, 2018 10:31AM Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy
May 22, 2018 05:51AM Spark Therapeutics (ONCE) and Pfizer (PFE) Highlight Data from Ongoing Phase 1/2 Clinical Trial of Investigational SPK-9001 for 15 Patients with Severe/Moderately-Severe Hemophilia B
May 22, 2018 02:00AM Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
May 22, 2018 02:00AM Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
May 22, 2018 02:00AM Spark Therapeutics and Pfizer Announce Data from 15 Participants with Hemophilia B Showing Persistent and Sustained Factor IX Levels with No Serious Adverse Events
May 8, 2018 07:30AM Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
May 8, 2018 07:30AM Spark Therapeutics Reports First Quarter 2018 Financial Results and Recent Business Progress
View More Recent Stories View Older Stories